Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Conclusions: This study demonstrated the efficacy and safety of the recommended dose level of blinatumomab in a high-risk adult R/R ALL population. Response rates in Japanese patients were consistent with those in global studies, and no new safety signals were identified.DisclosuresKobayashi: Ohtuka: Research Funding; Pfizer: Research Funding; Astellas: Research Funding. Zimmerman: Amgen Inc.: Employment, Equity Ownership. Minami: Kyowa-Kirin: Honoraria, Research Funding; MSD: Honoraria, Other: Clinical Trial, Research Funding; Ono Yakuhin: Honoraria, Other: Clinical Trial, Research Funding; Behringer: Honoraria, Research Funding; AstraZeneca: Other: Clinical Trial; Pfizer: Honoraria, Research Funding; Teijin Pharma: Research Funding; Astellas: Research Funding; Ohtsuka: Honoraria; Taiho: Honoraria, Other: Clinical Trial, Research Funding; Bristol-Myers Squibb: Honoraria, Other: Clinical Trial, Research Funding; Kowa: Honoraria; Eizai: Honoraria, Research Funding; Taisho-Toyama: Research Funding; DaiNihonSumitomo: Honoraria, Research Funding; DaiichiSankyo: Honoraria, Other: Clinical Trial, Research Funding; Chugai: Honoraria, Other: Clinical Trial, Research Funding; Janssen: Honoraria; Celgene: Clinical Trial, Honoraria; Takeda: Honoraria, Research Funding; Shire Japan: Honoraria; Eizai: Honoraria, Research Funding; Sanofi: Honoraria, Research Funding; Bayer: Honoraria, Other: Clinical Trial, Research Funding; Merck Serono: Honoraria; Nihon Shinyaku: Research Funding; Lilly:...

Source: Blood - November 21, 2018 Category: Hematology Authors: Kobayashi, Y., Zimmerman, Z. F., Oh, I., Maeda, Y., Minami, H., Miyamoto, T., Sakura, T., Iida, H., Chen, Y., Kiyoi, H. Tags: 612. Acute Lymphoblastic Leukemia: Clinical Studies Source Type: research